We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Oxurion NV | EU:OXUR | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 10,000,000 | 06:30:00 |
From Apr 2024 to Jun 2024
Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024
Leuven, BELGIUM – 23 May, 2024 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, held its annual shareholders’ meeting on May 16, 2024. The shareholders approved all items on the agenda of the annual shareholders’ meeting.
All documents pertaining to the annual shareholders' meeting held on May 16, 2024, can be consulted on Oxurion’s website Oxurion/shareholders.
About Oxurion
Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com.
Please contact for additional information:
| Oxurion NVPascal GhosonChief Executive Officerpascal.ghoson@oxurion.com | Backstage CommunicationJurgen VluijmansPartnerjurgen@backstagecom.be |
Attachment
1 Year Oxurion NV Chart |
1 Month Oxurion NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
